Fulcrum Therapeutics Inc. (FULC) Tops Q2 EPS by 2c

Fulcrum Therapeutics Inc. (NASDAQ: FULC) reported Q2 EPS of ($0.60), $0.02 better than the analyst estimate of ($0.62). Revenue for the quarter came in at $4.3 million versus the consensus estimate of $1.6 million.

For earnings history and earnings-related data on Fulcrum Therapeutics Inc. (FULC) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• The free USDA tool that tracks egg prices at $0.62/dozen before your data vendor does
• Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance